InSitu Biologics touted preclinical data for its non-opiate, hydrogel-based painkiller, AnestaGel, for use in peri-operative regional pain management. The St. Paul, Minn.-based company designs therapies using its Matrix biohydrogel material. Independent tests compared operative site injections of AnestaGel and Pacira Pharmaceutical’s (NSDQ:PCRX) Exparel. According to InSitu, the data showed that AnestaGel lasted longer and provided a […]